|
Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
|
Dec 2012
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
More is better: Combination therapies for myelodysplastic syndromes
|
Mar 2015
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes (MDS)
|
Mar 2015
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
|
Dec 2013
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes
|
Dec 2013
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): Cause or consequence?
|
Dec 2013
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes: State of the art pathology, diagnosis and management
|
Dec 2013
|
Best Pract Res Clin Haematol
|
myelodysplastic syndromes (MDS)
|
|
MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity?
|
Jun 2020
|
Best practice & research. Clinical haematology
|
myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)
|
|
Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality?
|
Jun 2020
|
Best practice & research. Clinical haematology
|
myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN)
|
|
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
|
Dec 2020
|
Best practice & research. Clinical haematology
|
myelodysplastic syndromes (MDS)
|
